Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07522645 · ClinicalTrials.gov registry record · NA
Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease
A NA study, sponsored by Kaiser Permanente.
- Active
- Registry status
- NA
- Development phase
- 22,000
- Enrollment target
NCT07522645 is a NA study that is active but no longer recruiting, run by Kaiser Permanente. The registered enrollment target is 22,000 participants.
The verdict
NCT07522645, a NA study, is active but no longer recruiting, sponsored by Kaiser Permanente.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 22,000 participants
- Enrollment target
Study Summary
The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are: 1. Do different outreach methods (such as text messages, secure portal messages, or email) increase short-term statin refill compared to usual care? 2. Among patients who do not initially refill their prescription, does changing the outreach method improve refill rates? The team with operational partners will evaluate the comparitive effectivessness of multiple messaging strategies delivered through existing health system communication channels, including SMS (text messaging), secure patient portal messages, non-secure email, and usual care (no additional outreach). Participants * Receive an initial outreach message encouraging statin refill (or usual care) Be monitored for statin refill within 14 days * Potentially receive a second outreach message using the same or a different communication method if they do not initially refill their prescription * Have their medication refill patterns tracked over time, including longer-term adherence outcomes
Interventions
- BEHAVIORAL SMS (Initial Outreach)
- BEHAVIORAL Secure Portal Message (Initial Outreach)
- BEHAVIORAL Non-secure Email (Initial Outreach)
- BEHAVIORAL SMS (Follow-up for Non-responders)
- BEHAVIORAL Secure Portal Message (Follow-up for Non-responders)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 22,000 participants |
| Start Date | 2026-04-14 |
| Est. Completion | 2028-12-31 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07522645
The ClinicalTrials.gov registry entry for NCT07522645 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 22,000 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Kaiser Permanente, which has 294 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which SMS (Initial Outreach) is the first listed.
NCT07522645 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07522645 about?
NCT07522645 is a clinical study titled "Adherence to Dyslipidemia Therapy: Harnessing Evidence From Randomized Evaluations in AtheroSclerotic CardioVascular Disease". The goal of the ADHERE-ASCVD study is to evaluate and optimize patient-facing messaging strategies to improve statin refill and adherence among adults with atherosclerotic cardiovascular disease (ASCVD) or diabetes. The main questions it aims to answer are: 1. Do different outreach methods (such a...
What is the current status of trial NCT07522645?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 22,000 participants. The study started on 2026-04-14. Estimated completion is 2028-12-31.
What interventions are being tested in trial NCT07522645?
The interventions under investigation include: SMS (Initial Outreach) (BEHAVIORAL), Secure Portal Message (Initial Outreach) (BEHAVIORAL), Non-secure Email (Initial Outreach) (BEHAVIORAL), SMS (Follow-up for Non-responders) (BEHAVIORAL), Secure Portal Message (Follow-up for Non-responders) (BEHAVIORAL).
Who is sponsoring clinical trial NCT07522645?
This trial is sponsored by Kaiser Permanente, which has 294 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.